The Treatment of Primary IgA Nephropathy: Change, Change, Change.
| Autor: | Caster DJ; Division of Nephrology and Hypertension, University of Louisville, Louisville, Kentucky., Lafayette RA; Division of Nephrology, Stanford University Medical Center, Stanford, California. Electronic address: czar@stanford.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | American journal of kidney diseases : the official journal of the National Kidney Foundation [Am J Kidney Dis] 2024 Feb; Vol. 83 (2), pp. 229-240. Date of Electronic Publication: 2023 Sep 23. |
| DOI: | 10.1053/j.ajkd.2023.08.007 |
| Abstrakt: | IgA nephropathy (IgAN) is the most common glomerular disease in the world. However, the approach to treatment remains controversial. There has been an explosion of clinical trials over the past decade both to further examine corticosteroid use and usher in additional treatment considerations, including 2 newly approved therapies for IgAN. Sodium glucose cotransporter 2 inhibitors are proving to be effective therapy across proteinuric chronic kidney diseases, and IgAN is not likely to be an exception. Further supportive agents are looking highly promising and so are novel agents that specifically focus on the pathophysiology of this disease, including endothelin blockade, complement inhibition, and B-cell targeted strategies. We suggest a present-day approach to treatment of individuals with IgAN, expose the limitations in our knowledge, and discuss new treatments that may arise, hoping they come with evidence about optimal utilization. Change appears to be inevitable for our approach to the treatment of IgA nephropathy. This is truly an exciting and optimistic time. (Copyright © 2023 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|